Korro Bio, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $6.4M | $2.3M | $0 | $0 | $14.1M |
| Operating income | -$121.9M | -$91.9M | -$84.5M | -$59.0M | -$84.0M |
| Operating expenses | $128.2M | $94.2M | $84.5M | $59.0M | $98.1M |
| Cash from operations | -$78.6M | -$60.1M | -$67.3M | -$53.6M | -$76.1M |
| Capital expenditure | $518,000 | $17.9M | $7.8M | $5.1M | $2.9M |
| Free cash flow | -$79.1M | -$78.0M | -$75.1M | -$58.8M | -$79.0M |
| Impairments | $30.9M | $0 | — | $0 | $0 |
| Total assets | $113.5M | $226.2M | $221.7M | $73.7M | $185.4M |
| Total liabilities | $62.1M | $65.8M | $51.8M | $8.9M | $54.5M |
Shares outstanding 14.4M · Free float 73.9%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.